Douglas L Arnold

Q: What Schools Are Affiliated With Douglas L Arnold

Douglas L Arnold is affiliated with the following schools: McGill University, University of Chicago, Johns Hopkins University, University of Toronto

Douglas L Arnold's AcademicInfluence.com Rankings

Douglas L Arnold

Mathematics

#5549

World Rank

#7803

Historical Rank

Applied Mathematics

#144

World Rank

#161

Historical Rank

Measure Theory

#791

World Rank

#1051

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Douglas L Arnold's Degrees

PhD Mathematics University of Chicago

Why Is Douglas L Arnold Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Douglas L Arnold's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. (2012) (1465)
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (2008) (1332)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (2017) (1170)
Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis (2017) (1107)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012) (1044)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (2012) (1037)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (2018) (559)
Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy (1996) (527)
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. (2001) (516)
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. (1998) (513)
Imaging axonal damage of normal-appearing white matter in multiple sclerosis. (1998) (505)
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial (2008) (476)
Reversible decreases in N‐acetylaspartate after acute brain injury (1995) (462)
Mesial temporal damage in temporal lobe epilepsy: a volumetric MRI study of the hippocampus, amygdala and parahippocampal region. (2003) (444)
Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging (2013) (335)
Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques (1992) (334)
Chemical pathology of acute demyelinating lesions and its correlation with disability (1995) (311)
Exploring Uncertainty Measures in Deep Networks for Multiple Sclerosis Lesion Detection and Segmentation (2018) (310)
Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. (2000) (310)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study (2014) (306)
Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease (1990) (306)
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. (2006) (290)
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study (2011) (288)
Incidence of acquired demyelination of the CNS in Canadian children (2009) (283)
Neuroimaging evidence of progressive neuronal loss and dysfunction in temporal lobe epilepsy (1999) (278)
Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis (2014) (251)
Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy (1997) (248)
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial (2016) (247)
Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporal lobe epilepsy: A series of 100 patients (1997) (242)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. (2015) (237)
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease (2011) (234)
Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton magnetic resonance spectroscopic images (1994) (232)
Robust Rician noise estimation for MR images (2010) (225)
Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis (1991) (206)
Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis (1994) (203)
The relationship between diffuse axonal damage and fatigue in multiple sclerosis. (2004) (202)
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations (2013) (199)
Aerobic conditioning in patients with mitochondrial myopathies: Physiological, biochemical, and genetic effects (2001) (191)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension (2018) (190)
Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. (1998) (190)
In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. (1999) (187)
EXCESSIVE INTRACELLULAR ACIDOSIS OF SKELETAL MUSCLE ON EXERCISE IN A PATIENT WITH A POST-VIRAL EXHAUSTION/FATIGUE SYNDROME A 31P Nuclear Magnetic Resonance Study (1984) (186)
Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo (1994) (184)
Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. (2002) (183)
Recovery of N‐acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy (1998) (180)
Functional brain reorganization for hand movement in patients with multiple sclerosis: defining distinct effects of injury and disability. (2002) (175)
Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. (1996) (174)
Alemtuzumab CARE-MS II 5-year follow-up (2017) (174)
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis (2014) (173)
Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. (2000) (171)
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? (2012) (169)
Texture analysis and morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra‐temporal partial epilepsy (2001) (168)
A proton magnetic resonance spectroscopy study of focal epilepsy in humans (1990) (168)
Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions (2008) (168)
Relating neocortical pathology to disability progression in multiple sclerosis using MRI (2004) (167)
Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b (2001) (166)
Short‐term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders (1995) (165)
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. (2015) (164)
Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. (1999) (164)
MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study (2011) (162)
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. (2007) (158)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. (2019) (151)
Evaluating intensity normalization on MRIs of human brain with multiple sclerosis (2011) (148)
Magnetic resonance spectroscopy and imaging of the thalamus in idiopathic generalized epilepsy. (2003) (139)
IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event (2006) (139)
Automated detection of focal cortical dysplasia lesions using computational models of their MRI characteristics and texture analysis (2003) (138)
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials (2020) (137)
Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes (2019) (137)
Effects of aerobic training in patients with mitochondrial myopathies (1998) (133)
Alemtuzumab CARE-MS I 5-year follow-up (2017) (132)
Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial (2016) (132)
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study (2016) (130)
2010 McDonald criteria for diagnosing pediatric multiple sclerosis (2012) (130)
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation (2013) (130)
MRI correlates of cognitive impairment in childhood-onset multiple sclerosis. (2011) (129)
In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondria1 disease (1991) (129)
Trial of Fingolimod versus Interferon Beta‐1a in Pediatric Multiple Sclerosis (2018) (127)
Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease (1993) (126)
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial (2016) (125)
Guidelines for using proton MR spectroscopy in multicenter clinical MS studies (2007) (123)
T2 Relaxometry Can Lateralize Mesial Temporal Lobe Epilepsy in Patients with Normal MRI (2000) (121)
Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors (2007) (120)
MR image-guided P-31 MR spectroscopy in the evaluation of brain tumor treatment. (1987) (117)
Neuroimaging in multiple sclerosis. (1995) (117)
Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading (1990) (116)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial (2019) (113)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial (2019) (112)
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS (2017) (112)
Quantitative magnetization transfer and myelin water imaging of the evolution of acute multiple sclerosis lesions (2010) (111)
1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. (2005) (110)
Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy (2000) (109)
Magnetization transfer can predict clinical evolution in patients with multiple sclerosis (2002) (108)
Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree (2000) (106)
Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion (2007) (100)
Regional variations in normal brain shown by quantitative magnetization transfer imaging (2004) (99)
Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? (1999) (98)
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE (2015) (97)
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis (2019) (97)
Is ictal recording mandatory in temporal lobe epilepsy? Not when the interictal electroencephalogram and hippocampal atrophy coincide. (2000) (96)
Trimmed-Likelihood Estimation for Focal Lesions and Tissue Segmentation in Multisequence MRI for Multiple Sclerosis (2011) (95)
Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations (2015) (93)
Neuronal metabolic dysfunction in patients with cortical developmental malformations (1998) (93)
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth (2014) (93)
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions (2018) (92)
MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group (2002) (91)
Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis (2006) (90)
A prospective, randomized, placebo‐controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results (2003) (89)
MRI in the diagnosis and management of multiple sclerosis (2002) (88)
Clinically feasible MTR is sensitive to cortical demyelination in MS (2013) (87)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis (2003) (87)
Magnetic Resonance Spectroscopy Guided Brain Tumor Resection: Differentiation Between Recurrent Glioma and Radiation Change in Two Diagnostically Difficult Cases (1998) (87)
Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases (2006) (86)
Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis (2010) (84)
Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. (2005) (83)
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial (2019) (83)
Short‐term aerobic training response in chronic myopathies (1999) (80)
Axonal dysfunction and disability in a relapse of multiple sclerosis: Longitudinal study of a patient (1997) (80)
Lesion distribution in children with clinically isolated syndromes (2008) (80)
EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis (2006) (80)
Gradient distortions in MRI: Characterizing and correcting for their effects on SIENA-generated measures of brain volume change (2010) (79)
Multiple Sclerosis Lesion Segmentation Using an Automatic Multimodal Graph Cuts (2009) (79)
Function and organization in dysgenic cortex. Case report. (1997) (78)
Mental fatigue alters the pattern and increases the volume of cerebral activation required for a motor task in multiple sclerosis patients with fatigue (2008) (78)
In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging (1998) (77)
Proton Magnetic Resonance Spectroscopic Imaging in Patients with Extratemporal Epilepsy (1998) (75)
Magnetic resonance spectroscopy: imaging axonal damage in MS (1999) (75)
ADP Recovery After a Brief Ischemic Exercise in Normal and Diseased Human Muscle — a 31P MRS Study (1996) (74)
Cerebral dysgenesis and lactic acidemia: an MRI/MRS phenotype associated with pyruvate dehydrogenase deficiency. (1994) (74)
Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study (2016) (73)
Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data (2021) (72)
Regional brain atrophy in children with multiple sclerosis (2011) (72)
Proton magnetic resonance spectroscopic imaging for discrimination of absence and complex partial seizures (1997) (72)
Computational Models of MRI Characteristics of Focal Cortical Dysplasia Improve Lesion Detection (2002) (70)
Morphometric MRI Analysis of the Parahippocampal Region in Temporal Lobe Epilepsy (2000) (70)
Serum neurofilament light as a biomarker in progressive multiple sclerosis (2020) (70)
Combined aerobic training and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase deficiency (1996) (70)
Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. (2000) (70)
Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis☆ (2013) (69)
A mitochondrial encephalomyopathy A combined 31P magnetic resonance and biochemical investigation (1985) (69)
Rotation-invariant multi-contrast non-local means for MS lesion segmentation (2015) (69)
Examination of the energetics of aging skeletal muscle using nuclear magnetic resonance. (1984) (68)
Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies (2014) (68)
Statistical power and prediction accuracy in multisite resting-state fMRI connectivity (2017) (68)
Temporally Consistent Probabilistic Detection of New Multiple Sclerosis Lesions in Brain MRI (2013) (67)
MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. (2018) (66)
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study (2014) (65)
Phase III dose‐comparison study of glatiramer acetate for multiple sclerosis (2011) (64)
Quantitative Determination of Regional Lesion Volume and Distribution in Children and Adults with Relapsing-Remitting Multiple Sclerosis (2014) (64)
Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. (1999) (63)
Changes in cognitive performance over a 1-year period in children and adolescents with multiple sclerosis. (2013) (62)
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study (2015) (62)
Entorhinal Cortex MRI Assessment in Temporal, Extratemporal, and Idiopathic Generalized Epilepsy (2003) (61)
The role of edema and demyelination in chronic T1 black holes: A quantitative magnetization transfer study (2005) (61)
Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis (2013) (61)
Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis (2015) (61)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial (2020) (60)
Five years of ocrelizumab in relapsing multiple sclerosis (2020) (59)
Effect of dimethyl fumarate on lymphocytes in RRMS (2019) (59)
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study (2014) (59)
Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients (2015) (57)
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study (2013) (57)
Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. (1985) (57)
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis (2014) (56)
The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. (1998) (56)
Mitochondrial disease. Pulmonary function, exercise performance, and blood lactate levels. (1995) (56)
Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution (2001) (56)
Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients (2005) (55)
Proton magnetic resonance spectroscopic imaging suggests progressive neuronal damage in human temporal lobe epilepsy. (2002) (55)
Axonal injury in the cerebral normal-appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter (2006) (55)
White matter integrity and math performance in pediatric multiple sclerosis: a diffusion tensor imaging study (2011) (54)
Imaging of axonal damage in vivo in Rasmussen's syndrome. (1995) (54)
Ca2+-ATPase deficiency in a patient with an exertional muscle pain syndrome. (1988) (54)
Magnetic resonance spectroscopy in Niemann-Pick disease type C: correlation with diagnosis and clinical response to cholestyramine and lovastatin. (1994) (54)
Automated quality control of brain MR images (2008) (53)
Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis (2003) (53)
Impairment of muscle mitochondrial oxidative metabolism in McArdle's disease (1996) (53)
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial (2016) (52)
Spatial Extent of Neuronal Metabolic Dysfunction Measured by Proton MR Spectroscopic Imaging in Patients with Localization‐Related Epilepsy (2000) (52)
Automated Estimation of Brain Volume in Multiple Sclerosis with BICCR (2001) (51)
Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. (2009) (50)
Significance of mesial temporal atrophy in relation to intracranial ictal and interictal stereo EEG abnormalities. (1996) (50)
Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI Using Conditional Random Fields (2012) (50)
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study (2018) (50)
Predicting surgical outcome in temporal lobe epilepsy patients using MRI and MRSI (2002) (49)
Proton magnetic resonance spectroscopic images and MRI volumetric studies for lateralization of temporal lobe epilepsy. (1995) (49)
Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging (2006) (48)
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials (2014) (48)
Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis (2019) (47)
Diffusion tensor imaging and cognitive speed in children with multiple sclerosis (2011) (47)
Characterization of astrocytomas, meningiomas, and pituitary adenomas by phosphorus magnetic resonance spectroscopy. (1991) (47)
Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: Consensus report of the white matter study group (2005) (47)
Bayesian MS Lesion Classification Modeling Regional and Local Spatial Information (2006) (47)
Proton Magnetic Resonance Spectroscopic Imaging Can Predict Length of Survival in Patients with Supratentorial Gliomas (2003) (46)
Improved correlation between scores on the expanded disability status scale and cerebral lesion load in relapsing-remitting multiple sclerosis. Results of the application of new imaging methods. (1998) (45)
Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. (2003) (45)
Proton MR spectroscopy in multiple sclerosis. (2000) (45)
Elevated serum inflammatory markers in post-poliomyelitis syndrome (2008) (44)
Surface‐based analysis reveals regions of reduced cortical magnetization transfer ratio in patients with multiple sclerosis: A proposed method for imaging subpial demyelination (2014) (44)
Virus-induced autoimmune reactions in the CNS. (2001) (44)
Application of calibrated fMRI in Alzheimer's disease (2017) (44)
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. (2010) (43)
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis (2014) (42)
Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination (2016) (42)
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a (2018) (41)
Quantitative magnetization transfer imaging made easy with qMTLab: Software for data simulation, analysis, and visualization (2015) (41)
Imaging of repeated episodes of demyelination and remyelination in multiple sclerosis (2014) (41)
Dual‐temporal resolution dynamic contrast‐enhanced MRI protocol for blood–brain barrier permeability measurement in enhancing multiple sclerosis lesions (2011) (40)
Imaging outcome measures of neuroprotection and repair in MS (2019) (40)
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial (2020) (40)
High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS (2019) (40)
N‐acetylaspartate: Usefulness as an indicator of viable neuronal tissue (2001) (40)
Interferon β-1b and glatiramer acetate effects on permanent black hole evolution (2011) (40)
White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders (2017) (39)
ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis (2017) (39)
Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE (2020) (39)
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study (2014) (38)
Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis (2016) (37)
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. (2004) (37)
Fatigue in Post‐poliomyelitis Syndrome: Association With Disease‐Related, Behavioral, and Psychosocial Factors (2009) (37)
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial (2021) (37)
Evidence for mitochondrial dysfunction in patients with alternating hemiplegia of childhood (1993) (37)
Biological markers in the diagnosis and treatment of ALS (1999) (36)
Prediction of Disease Progression in Multiple Sclerosis Patients using Deep Learning Analysis of MRI Data (2019) (36)
MR spectroscopy and imaging in metabolic myopathies. (2000) (36)
Metabolic Changes in Cerebral Gliomas Within Hours of Treatment With Intra-Arterial BCNU Demonstrated by Phosphorus Magnetic Resonance Spectroscopy (1987) (35)
Monophasic demyelination reduces brain growth in children (2017) (35)
MRI in the evaluation of pediatric multiple sclerosis (2016) (35)
A surface‐in gradient of thalamic damage evolves in pediatric multiple sclerosis (2019) (35)
Combining Robust Expectation Maximization and Mean Shift algorithms for Multiple Sclerosis Brain Segmentation (2008) (34)
Estimating and accounting for the effect of MRI scanner changes on longitudinal whole-brain volume change measurements (2019) (34)
Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study (2019) (34)
1H NMR characterization of normal human cerebrospinal fluid and the detection of methylmalonic acid in a vitamin B12 deficient patient (1991) (33)
Probabilistic Multiple Sclerosis Lesion Classification Based on Modeling Regional Intensity Variability and Local Neighborhood Information (2015) (33)
Reproducibility of quantitative magnetization‐transfer imaging parameters from repeated measurements (2010) (32)
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study (2018) (32)
Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials (2013) (31)
Abnormal oxidative metabolism in exercise in exercise intolerance of undetermined origin (1997) (31)
Intracellular phosphates in inclusion body myositis—A 31P magnetic resonance spectroscopy study (1998) (30)
MS Lesion Segmentation using Markov Random Fields (2009) (29)
The lesions of multiple sclerosis. (2002) (29)
Memory Performance and Normalized Regional Brain Volumes in Patients with Pediatric-Onset Multiple Sclerosis (2012) (29)
The role of MRS and fMRI in multiple sclerosis. (2006) (29)
Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. (2000) (29)
Magnetic Resonance Spectroscopy in Epilepsy: Clinical Issues (2002) (29)
Imaging axonal damage in multiple sclerosis by means of MR spectroscopy (2000) (28)
Secondary Progressive Multiple Sclerosis New Insights (2021) (28)
Magnetization transfer ratio recovery in new lesions decreases during adolescence in pediatric-onset multiple sclerosis patients (2014) (28)
Improved Precision in the Measurement of Longitudinal Global and Regional Volumetric Changes via a Novel MRI Gradient Distortion Characterization and Correction Technique (2010) (28)
Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis (2017) (28)
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial (2013) (28)
Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis (2008) (28)
Large, nonplateauing relationship between clinical disability and cerebral white matter lesion load in patients with multiple sclerosis. (2012) (28)
Secondary Progressive Multiple Sclerosis (2021) (27)
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS (2008) (27)
Early Metabolic Changes Following Chemotherapy of Human Gliomas In Vivo Demonstrated by Phosphorus Magnetic Resonance Spectroscopy (1989) (27)
A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis (2017) (27)
Lateralization of Temporal Lobe Epilepsy (TLE) and Discrimination of TLE from Extra‐TLE Using Pattern Analysis of Magnetic Resonance Spectroscopic and Volumetric Data (2000) (27)
Relation of Interictal Spike Frequency to 1H‐MRSI‐Measured NAA/Cr (1999) (26)
Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma (2008) (26)
Comparison of Multiple Sclerosis Cortical Lesion Types Detected by Multicontrast 3T and 7T MRI (2019) (26)
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS (2016) (26)
Temporal Hierarchical Adaptive Texture CRF for Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI (2015) (25)
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis (2017) (25)
Intracortical inhibition abnormality during the remission phase of multiple sclerosis is related to upper limb dexterity and lesions (2016) (24)
Evidence for neuroprotection and remyelination using imaging techniques (2007) (24)
Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial (2002) (24)
The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk (2019) (24)
Glutaric acidemia type II: neuroimaging and spectroscopy evidence for developmental encephalomyopathy. (1995) (23)
Muscle phosphorus magnetic resonance spectroscopy oxidative indices correlate with physical activity (2000) (23)
Statistics for Investigation of Multimodal MR Imaging Data and an Application to Multiple Sclerosis Patients (1996) (23)
Proton MR spectroscopy to assess axonal damage in multiple sclerosis and other white matter disorders. (2000) (23)
Non-Local Means Inpainting of MS Lesions in Longitudinal Image Processing (2015) (22)
1H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis (2009) (22)
Neuroimaging in amyotrophic lateral sclerosis (2003) (22)
Adaptive multi-level conditional random fields for detection and segmentation of small enhanced pathology in medical images (2016) (22)
Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies (2016) (22)
Heterogeneity of T‐lymphocyte function in primary progressive multiple sclerosis: Relation to magnetic resonance imaging lesion volume (2000) (22)
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study (2018) (21)
Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial (2017) (21)
Proton Magnetic Resonance Spectroscopic Imaging Studies in Patients with Newly Diagnosed Partial Epilepsy (2000) (21)
Masquerades of Acquired Demyelination in Children (2013) (21)
1 H-MRS quantification of tNA and tCr in patients with multiple sclerosis : a meta-analytic review (2005) (21)
Multiple Sclerosis Lesions Segmentation using Spectral Gradient and Graph Cuts (2008) (20)
White matter plasticity and maturation in human cognition (2019) (20)
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation (2021) (20)
Axonal Damage in Multiple Sclerosis Patients with High versus Low Expanded Disability Status Scale Score (2004) (20)
Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial (2018) (19)
Statistical Analysis of Longitudinal MRI Data: Applications for Detection of Disease Activity in MS (2002) (19)
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial (2021) (19)
Magnetic Resonance Spectroscopy in Multiple Sclerosis (2001) (19)
Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study (S49.001) (2016) (18)
Spectroscopic imaging of frontal neuronal dysfunction in hyperekplexia. (1998) (18)
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial (2021) (18)
How patients with multiple sclerosis acquire disability (2022) (18)
IMaGe: Iterative Multilevel Probabilistic Graphical Model for Detection and Segmentation of Multiple Sclerosis Lesions in Brain MRI (2015) (18)
An Object-Based Method for Rician Noise Estimation in MR Images (2009) (18)
Local Indicators of Spatial Autocorrelation (LISA): Application to Blind Noise-Based Perceptual Quality Metric Index for Magnetic Resonance Images (2019) (18)
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial (2022) (18)
Altered resting-state functional connectivity in cognitively preserved pediatric-onset MS patients and relationship to structural damage and cognitive performance (2016) (18)
Modeling in vivo recovery of intracellular pH in muscle to provide a novel index of proton handling: Application to the diagnosis of mitochondrial myopathy (2001) (17)
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results (2021) (17)
Using Deep Learning Algorithms to Automatically Identify the Brain MRI Contrast: Implications for Managing Large Databases (2018) (17)
Deep grey matter injury in multiple sclerosis: A NAIMS consensus statement. (2021) (17)
Changes observed in multiple sclerosis using magnetic resonance imaging reflect a focal pathology distributed along axonal pathways (2005) (16)
MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis (2017) (16)
Propagating Uncertainty Across Cascaded Medical Imaging Tasks for Improved Deep Learning Inference (2019) (16)
Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease (2016) (16)
Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions (2020) (16)
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring (2020) (15)
Adaptive Voxel, Texture and Temporal Conditional Random Fields for Detection of Gad-Enhancing Multiple Sclerosis Lesions in Brain MRI (2013) (15)
Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004) (2016) (15)
MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b (2016) (15)
Bayesian Classification of Multiple Sclerosis Lesions in Longitudinal MRI Using Subtraction Images (2010) (15)
Neuronal dysfunction in children with newly diagnosed temporal lobe epilepsy. (2000) (14)
Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001) (2013) (14)
P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN β -1a–controlled OPERA I and OPERA II studies (2017) (14)
Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis (2020) (14)
Intracellular phosphates in inclusion body myositis--a 31P magnetic resonance spectroscopy study. (1998) (14)
Quantitative Measurement of tissue damage and recovery within new T2w lesions in pediatric- and adult-onset multiple sclerosis (2015) (14)
Detection of Gad-Enhancing Lesions in Multiple Sclerosis Using Conditional Random Fields (2010) (14)
Multivariate Statistics for Detection of MS Activity in Serial Multimodal MR Images (2003) (13)
Incidence and prevalence of MS in children (2018) (13)
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN (2018) (13)
Automated separation of diffusely abnormal white matter from focal white matter lesions on MRI in multiple sclerosis (2019) (12)
BG-12 Increases the Proportion of Patients Free of Clinical and Radiologic Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (PD5.005) (2012) (12)
CNN Detection of New and Enlarging Multiple Sclerosis Lesions from Longitudinal Mri Using Subtraction Images (2020) (12)
The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes (2021) (12)
Association of cerebral dysgenesis and lactic acidemia with X-linked PDH E1 alpha subunit mutations in females. (1995) (12)
Predicting Future Disease Activity and Treatment Responders for Multiple Sclerosis Patients Using a Bag-of-Lesions Brain Representation (2017) (12)
Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes (2021) (12)
Magnetic resonance spectroscopy for monitoring neuronal integrity in amyotrophic lateral sclerosis. (2006) (12)
Deep learning segmentation of orbital fat to calibrate conventional MRI for longitudinal studies (2019) (12)
Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM (2016) (12)
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. (2021) (12)
Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy (2002) (11)
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. (2020) (11)
Magnetization transfer ratio is unable to lateralize epileptic foci in patients with temporal lobe epilepsy. (2000) (11)
Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? (2009) (11)
No-reference quality measure in brain MRI images using binary operations, texture and set analysis (2017) (11)
High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study (2019) (11)
Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters (2018) (11)
Normalization of White Matter Intensity on T1‐Weighted Images of Patients with Acquired Central Nervous System Demyelination (2015) (11)
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study (2020) (11)
Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes (2021) (11)
T2 Relaxometry Can Lateralize Mesial Temporal Lobe Epilepsy in Patients with Normal MRI Volume 11, Number 6, Part 2 (2000), pages 739–746 (2001) (10)
Improving Pathological Structure Segmentation via Transfer Learning Across Diseases (2019) (10)
Optimal Gaussian Mixture Models of Tissue Intensities in Brain MRI of Patients with Multiple-Sclerosis (2010) (10)
Clinical Efficacy of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P07.097) (2013) (10)
Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations (2015) (10)
Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial (2016) (10)
Brain phosphorus magnetic resonance spectroscopy in acute bacterial meningitis. (1989) (9)
Delineation of cortical pathology in multiple sclerosis using multi-surface magnetization transfer ratio imaging (2016) (9)
Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis (2016) (9)
MRI and Proton MRS in the Evaluation of Multiple Sclerosis (1997) (9)
Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: now you see them, now you don’t (2014) (9)
Phosphorus magnetic resonance spectroscopy of brain in mitochondrial cytopathies (1990) (9)
Durable Effect of Alemtuzumab on MRI Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-Year Follow-up of CARE-MS II (P7.249) (2015) (9)
Axonal Injury and Disability in Multiple Sclerosis: Magnetic Resonance Spectroscopy as a Measure of Dynamic Pathological Change in White Matter (2001) (9)
Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy (2013) (9)
Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis (2016) (9)
Lesion Detection, Segmentation and Prediction in Multiple Sclerosis Clinical Trials (2017) (9)
Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI (2018) (9)
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials (2021) (9)
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years (2022) (9)
Cognitive and Behavioral Functioning in Childhood Acquired Demyelinating Syndromes (2016) (8)
A Generative Model for Automatic Detection of Resolving Multiple Sclerosis Lesions (2014) (8)
The relation of focal white matter signal abnormality and focal volume loss in multiple sclerosis (2007) (8)
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis (2020) (8)
Efficacy of Ocrelizumab in Patients with Relapsing Multiple Sclerosis: Pooled Analysis of Two Identical Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled Studies (S49.003) (2016) (8)
Durable Effect of Alemtuzumab on MRI Activity in Treatment-Naive Active Relapsing-Remitting Multiple Sclerosis Patients: 4-Year Follow-up of CARE-MS I (P7.246) (2015) (8)
Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much? (2009) (8)
Efficacy and Safety of Alemtuzumab in Treatment-Naive Patients with Relapsing-Remitting MS: Four-Year Follow-up of the CARE-MS I Study (2015) (8)
Ozanimod Demonstrates Efficacy and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM) (P3.396) (2018) (8)
Patients with Active RRMS and an Inadequate Response to Prior Therapy Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS II Study (P3.022) (2016) (8)
Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis (2018) (8)
Hierarchical Conditional Random Fields for Detection of Gad-Enhancing Lesions in Multiple Sclerosis (2012) (8)
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial (2022) (8)
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy (S01.004) (2012) (8)
Bayesian framework inspired no-reference region-of-interest quality measure for brain MRI images (2017) (7)
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naïve Patients (S01.006) (2012) (7)
The clique potential of Markov random field in a random experiment for estimation of noise levels in 2D brain MRI (2013) (7)
Chapter 10 Magnetic Resonance Imaging and Spectroscopy: Insights into the Pathology and Pathophysiology of Multiple Sclerosis (2003) (7)
Efficacy Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Adults with Relapsing Multiple Sclerosis (P7.198) (2015) (7)
Optimal selection of regularization parameter in total variation method for reducing noise in magnetic resonance images of the brain (2014) (7)
Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis (2015) (7)
Incidence of Infection Decreases Over Time in Alemtuzumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis: 4-Year Follow-up of the CARE-MS Studies (P7.265) (2015) (7)
Imaging of Demyelination and Remyelination in Multiple Sclerosis (2013) (7)
Pooled Analyses from the ALLEGRO and BRAVO Trials on the Safety and Tolerability of Laquinimod as a Multiple Sclerosis Treatment (P04.132) (2012) (7)
Brain volume loss in individuals over time: Source of variance and limits of detectability (2020) (7)
Incidence and Timing of Thyroid Adverse Events in Patients with RRMS Treated with Alemtuzumab through 5 Years of the CARE-MS Studies (P2.086) (2016) (7)
Improving the SIENA performance using BEaST brain extraction (2018) (7)
Clinical Efficacy of Laquinimod for the Treatment of Multiple Sclerosis; Pooled Analyses from the ALLEGRO and BRAVO Phase III Trials (S01.007) (2012) (7)
Muscle high-energy phosphates in central nervous system disorders. The phosphorus MRS experience (1997) (7)
Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (2018) (7)
Erratum to: Optimal selection of regularization parameter in total variation method for reducing noise in magnetic resonance images of the brain (2014) (6)
Safety and Tolerability Results From the DECIDE Study: A Phase 3 Active-Comparator Study of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis (P7.230) (2015) (6)
white matter lesion load in patients with secondary progressive multiple sclerosis (2009) (6)
Chronic lesion activity and disability progression in secondary progressive multiple sclerosis (2022) (6)
Alemtuzumab Slows Brain Volume Loss Over 4 Years Despite Most Relapsing-Remitting Multiple Sclerosis Patients Not Receiving Treatment for 3 Years (P7.263) (2015) (6)
Use of Imaging in Multiple Sclerosis (2010) (6)
Brain volume and fatigue in patients with postpoliomyelitis syndrome. (2014) (6)
Proton magnetic resonance spectroscopy in brain white matter disorders (1997) (6)
Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study) (2013) (6)
Increased mental health care use by mothers of children with multiple sclerosis (2020) (6)
Corrigendum to “Gradient distortions in MRI: Characterizing and correcting for their effects on SIENA-generated measures of brain volume change” [NeuroImage 49 (2010) 1601–1611] (2010) (6)
Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: Primary Results of the DECIDE Study (S4.003) (2015) (6)
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study (2022) (6)
No Evidence for Impairment of Venous Hemodynamics in Children or Young Adults with Pediatric-Onset Multiple Sclerosis (2013) (6)
Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101) (2013) (6)
The Metabolic Epicenter of Supratentorial Gliomas: A 1H-MRSI Study (2009) (6)
Evaluation of no evidence of progression using composite outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial (2016) (6)
Path Sampling to Compute Integrated Likelihoods: An Adaptive Approach (2009) (6)
Proton Magnetic Resonance Spectroscopy (2002) (6)
Effect of Alemtuzumab vs. Rebif(R) on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study (S11.006) (2012) (6)
N-acetylaspartate: A marker of neuronal integrity. Authors' reply (2001) (5)
Effect of BG-12 on Brain Atrophy and Lesions Volume: MRI Results from the DEFINE Study during First and Second Year of Treatment (IN3-2.002) (2012) (5)
Image Quality Evaluation in Clinical Research: A Case Study on Brain and Cardiac MRI Images in Multi-Center Clinical Trials (2018) (5)
Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017) (2015) (5)
MRI inter-packet movement correction for images acquired with non-complementary data (2008) (5)
Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study (S51.001) (2016) (5)
ADVANCE Phase 3 Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis: Patient Baseline Characteristics (P01.133) (2012) (5)
Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174) (2013) (5)
Clinical Efficacy and Safety of Peginterferon beta-1a in Relapsing Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S31.006) (2013) (5)
Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis. (2019) (5)
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study (2020) (5)
Durable Effect of Alemtuzumab on Clinical Outcomes in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients: Four-Year Follow-up of CARE-MS I (S4.007) (2015) (5)
Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis (P7.201) (2015) (5)
ASCEND Phase 3 Trial Open-Label Extension Study Results: Natalizumab May Delay Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (P5.330) (2017) (5)
Diagnostic Tests in Neurology (1991) (5)
Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study (2013) (5)
CNN Prediction of Future Disease Activity for Multiple Sclerosis Patients from Baseline MRI and Lesion Labels (2018) (5)
The place of MRI in monitoring the individual MS patient (2007) (5)
Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise (2021) (4)
Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) (2019) (4)
Counterfactual Image Synthesis for Discovery of Personalized Predictive Image Markers (2022) (4)
Brain MRI Intensity Inhomogeneity Correction Using Region of Interest, Anatomic Structural Map, and Outlier Detection (2016) (4)
Serum Neurofilament Light (NfL): Towards a Blood Test for Prognosis and Disease/Treatment Monitoring in Multiple Sclerosis Patients (S24.003) (2018) (4)
A new metabolic myopathy: a malate-aspartate-shuttle defect (1986) (4)
CLINICAL AND NEURORADIOLOGICAL EFFECT OF BG-12 (DIMETHYL FUMARATE) IN SUBGROUPS OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF THE PHASE 3 DEFINE AND CONFIRM STUDIES (2013) (4)
Trial Designs Likely to Meet Valid Long-Term Alzheimer's Disease Progression Effects: Learning from the Past, Preparing for the Future (2009) (4)
Normalization of Magnetization Transfer Ratio MRI For Multicentre Clinical Trials (2010) (4)
The Efficacy of Alemtuzumab Is Maintained in Patients Who Develop Thyroid Adverse Events (P7.272) (2015) (4)
Surface-based techniques reveal regions of reduced cortical magnetization transfer ratio in patients with MS (2009) (4)
Ocrelizumab May Reduce Tissue Damage in Chronic Active Lesions as Measured by Change in T1 Hypo-Intensity of Slowly Evolving Lesions in Patients With Primary Progressive Multiple Sclerosis (P3.376) (2018) (4)
Magnetic resonance spectroscopy of multiple sclerosis: imaging axonal damage (2001) (4)
Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria (2022) (4)
Time Course of Postoperative Recovery of N‐Acetyl‐Aspartate in Temporal Lobe Epilepsy (2001) (4)
Metabolic and functional imaging of brain tumors (2001) (4)
Effects of BG-12 on Magnetization Transfer Ratio in Whole Brain and Normal-Appearing Brain Tissue: Findings from the DEFINE Study (S11.004) (2012) (4)
Regions of reduced cortical magnetization transfer ratio detected in MS patients using surface-based techniques (2009) (4)
Slowly expanding lesions are a marker of progressive MS – No (2021) (4)
Evidence for use of glatiramer acetate in multiple sclerosis (2005) (4)
Axonal pathology in patients with multiple sclerosis: evidence from in vivo proton magnetic resonance spectroscopy (2007) (4)
Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: 2-Year Follow-up Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI) (2013) (4)
Factors associated with health care utilization in pediatric multiple sclerosis. (2019) (4)
Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.006) (2018) (4)
Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093) (2013) (4)
Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation. (2021) (3)
RRMS Patients Switching from SC IFNB-1a to Alemtuzumab in the CARE-MS I and II Extension Study Have a Reduced Rate of Brain Volume Loss (P6.183) (2016) (3)
Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.002) (2016) (3)
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination (2021) (3)
Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis (2018) (3)
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase 1 trial (Annals of Neurology (2007) (399-495)) (2008) (3)
Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome (2021) (3)
Relapse Outcomes with Alemtuzumab vs IFNB-1a in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.098) (2013) (3)
Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis (2021) (3)
MT-1303, a novel selective s1p1 receptor modulator in RRMS - results of a placebo controlled, double blind phase II trial (momentum) (2015) (3)
Seeing injectable MS therapies differently (2009) (3)
Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif(R) in Multiple Sclerosis I (CARE-MS I) (S41.006) (2012) (3)
Standardized quality metric system for structural brain magnetic resonance images in multi-center neuroimaging study (2018) (3)
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials (2022) (3)
Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (S6.002) (2018) (3)
The spatial statistics of structural magnetic resonance images: application to post-acquisition quality assessment of brain MRI images (2017) (3)
Uncertainty for Safe Utilization of Machine Learning in Medical Imaging and Clinical Image-Based Procedures: First International Workshop, UNSURE 2019, and 8th International Workshop, CLIP 2019, Held in Conjunction with MICCAI 2019, Shenzhen, China, October 17, 2019, Proceedings (2019) (3)
Effect of Ocrelizumab on Disability Progression in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.008) (2016) (3)
Is It Possible to Differentiate the Impact of Pediatric Monophasic Demyelinating Disorders and Multiple Sclerosis After a First Episode of Demyelination? (2014) (3)
MRI Visualization of Multiple Sclerosis (2004) (3)
Influence of the training library composition on a patch-based label fusion method: Application to hippocampus segmentation on the ADNI dataset (2011) (3)
Safety and Tolerability Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Relapsing Multiple Sclerosis (P7.199) (2015) (3)
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study (2022) (3)
The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. (2022) (3)
Rate of Brain Volume Loss with Long-Term Delayed-Release Dimethyl Fumarate Treatment in Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Results from ENDORSE (P3.061) (2016) (3)
061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE) (2018) (3)
Magnetic resonance imaging as a surrogate for treatment effect on multiple sclerosis relapses (2009) (3)
Clinical and Magnetic Resonance Imaging Results From RADIANCE Part B, a Multicenter, Randomized, Double-Blind, Phase 3 Trial of Ozanimod Versus Intramuscular Interferon β-1a in Relapsing Multiple Sclerosis (RMS) (P3.410) (2018) (3)
Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes (2018) (3)
Redefining multiple sclerosis phenotypes using MRI (2019) (3)
Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130) (2020) (3)
P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies (2017) (2)
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS (2022) (2)
Treatment-Naive Patients with Active RRMS Who Received Alemtuzumab Demonstrate Durable Suppression of New MRI Lesion Formation: 5-Year Follow-Up of the CARE-MS I Study (S51.002) (2016) (2)
Defining multiple sclerosis subtypes using machine learning (2019) (2)
Efficacy of Alemtuzumab vs IFNB-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II): Subgroup Analysis by Previous Disease Modifying Therapy (DMT) Use (P07.111) (2013) (2)
COENZYME Q. AUTHORS' REPLY (1993) (2)
Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P01.130) (2012) (2)
Object-based Rician Noise Estimation for MR Images (2009) (2)
PO129 Neda analysis by epoch in the opera studies of ocrelizumab (2017) (2)
PND63 Effects of BG-12 on Quality of Life in Relapsing–Remitting Multiple Sclerosis: Findings From the Phase 3 Define Study (2012) (2)
Optimizing Operating Points for High Performance Lesion Detection and Segmentation Using Lesion Size Reweighting (2021) (2)
Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective (2022) (2)
Regional Brain Atrophy in Multiple Sclerosis : increasing sensitivity to differences in relapsing-remitting and secondary-progressive disease (2001) (2)
Relapse Outcomes with Alemtuzumab vs. Rebif® in Treatment-Naïve Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary Endpoints (PD5.004) (2012) (2)
Interim Analysis of 2-year Clinical Efficacy and Safety of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S4.005) (2014) (2)
Assessing the differential sensitivities of wave-CAIPI ViSTa myelin water fraction and magnetization transfer saturation for efficiently quantifying tissue damage in MS. (2021) (2)
Improvement in Clinical Outcomes in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients Who Switched From Subcutaneous Interferon Beta-1a to Alemtuzumab (P7.270) (2015) (2)
Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy (2014) (2)
Treatment-Naive Patients with Active RRMS Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS I Study (S51.004) (2016) (2)
148Immunoablative therapy with purified autologous stem cells rescue for the treatment of poor prognosis MS (2003) (2)
Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study (2017) (2)
Neuroradiological efficacy of oral BG-12 for relapsing–/INS;remitting multiple sclerosis (RRMS): Integrated analysis of the Phase 3 DEFINE and CONFIRM studies (2013) (2)
Daclizumab HYP Reduced Brain MRI Lesion Activity Compared With Interferon Beta-1a: Results from the DECIDE Study (P7.252) (2015) (2)
Durable Efficacy in RRMS Patients Receiving Two Annual Courses of Alemtuzumab and No Additional Treatment for 4 Years: Pooled Analysis of CARE-MS I and II (S51.005) (2016) (2)
Long-Term Efficacy in MRI and No Evidence of Disease Activity Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Peginterferon Beta-1a (P7.266) (2015) (2)
Exploratory MRI Biomarkers of Opicinumab (Anti-LINGO-1) Show Stabilization of Pre-existing T2 Lesions in Relapsing Multiple Sclerosis: Results from the Phase 2b SYNERGY Trial (P2.100) (2017) (2)
Saliency Based Deep Neural Network for Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI (2019) (2)
Natalizumab-Treated Patients with Multiple Sclerosis Have Low Rates of Brain Volume Decrease and Low MRI Disease Activity in the Long-term STRATA Study (P7.260) (2015) (2)
STRATEGIES FOR MONITORING AND ASSESSING THERAPY (2006) (2)
Longitudinal change in Paced Auditory Serial Addition Test (PASAT) performance following immunoablative therapy and haematopoietic stem cell transplant in multiple sclerosis (2016) (2)
Slowing of Brain Volume Loss in Patients With Relapsing-Remitting Multiple Sclerosis After Switching From Subcutaneous Interferon Beta-1a to Alemtuzumab (P7.264) (2015) (2)
Five-Year Follow-up of Delayed-Release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis: MRI Outcomes from DEFINE, CONFIRM, and ENDORSE (P7.262) (2015) (2)
Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials (2018) (2)
Predictors of an Opicinumab Treatment Effect and Identification of an Efficacy Subpopulation: A Post hoc Analysis of the SYNERGY Study (P3.408) (2018) (2)
Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: Early Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI) (2011) (2)
Phase 2 AFFINITY trial evaluates opicinumab in a targeted population of patients with relapsing multiple sclerosis: rationale, design and baseline characteristics (2018) (2)
Switching to Alemtuzumab From Subcutaneous Interferon Beta-1a After CARE-MS II Further Improved MRI Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis (P7.248) (2015) (2)
Five-year outcomes of halt-MS: high-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe relapsing-remitting multiple sclerosis (2016) (2)
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis (2020) (2)
Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis I (CARE-MS I) (S41.007) (2012) (2)
Long-Term Responders from the CARE-MS I Study: No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment (P3.054) (2016) (2)
Author Correction: Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data (2021) (2)
A power analysis for multisite studies in resting-state functional connectivity, with an application to clinical trials in Alzheimer's disease (2013) (2)
Statistical power and measurement bias in multisite resting-state fMRI connectivity (2016) (2)
056 Efficacy and safety of the Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis over 48 weeks: a randomized, placebo-controlled, phase 2 study (2019) (1)
Robust automatic segmentation and characterization of lateral ventricle size in the ADNI cohort (2010) (1)
Effects of temporal resolution on blood-brain barrier permeability measurement with Dynamic Contrast Enhanced MRI in multiple sclerosis enhancing lesions (2010) (1)
The search for the missing links in multiple sclerosis (2007) (1)
Cohort Bias Adaptation in Aggregated Datasets for Lesion Segmentation (2021) (1)
Prospective characterization of children positive for anti-MOG antibodies meeting Multiple Sclerosis diagnostic criteria (2019) (1)
ESTIMATING AND ACCOUNTING FOR THE EFFECT OF MRI SCANNER HARDWARE CHANGES ON LONGITUDINAL WHOLE-BRAIN ATROPHY MEASUREMENTS (2016) (1)
Sustained low rate of brain volume loss with long-term delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis patients: results from the ENDORSE study (2015) (1)
beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis (2002) (1)
Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) (2019) (1)
Impact Of Obstructive Sleep Apnea-Hypopnea Treatment On Fatigue In Multiple Sclerosis (2010) (1)
Disease Management in Multiple Sclerosis (2005) (1)
Measuring injury and repair of myelin and neurons in multiple sclerosis. (2005) (1)
Combined MRI Measure of Active Lesions and Brain Atrophy as a Surrogate for Disability in Multiple Sclerosis: A Meta-Analysis of Randomized Trials (P07.096) (2013) (1)
Baseline Characteristics of Pediatric Patients with Multiple Sclerosis Enrolled in the PARADIGMS Study: A Randomized, Double-Blind Study of Fingolimod versus Interferon-β-1a (P1.347) (2017) (1)
Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial (2023) (1)
086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study (2018) (1)
Multiple sclerosis (PP-038) (2010) (1)
Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P07.102) (2012) (1)
Magnetization Transfer Ratio Imaging Is Feasible in Large Multicenter MS Trials (2010) (1)
Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study (S12.006) (2017) (1)
Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis (2022) (1)
MUSCLE ACIDOSIS IN POST-VIRAL FATIGUE (1984) (1)
Rate of Agreement for Manual and Automated Techniques for Determination of New T2 Lesions in Children with Multiple Sclerosis and Acute Demyelination (P2.242) (2014) (1)
Six-year follow-up of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM and ENDORSE (2015) (1)
Proton MR Spectroscopic Imaging in The Investigation of Patients with Temporal Lobe Epilepsy (1994) (1)
Alemtuzumab-Treated Patients Experienced Decreased MRI Disease Activity and Slowing of Brain Volume Loss Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS I (TOPAZ Study) (S36.003) (2018) (1)
Segmentation-Consistent Probabilistic Lesion Counting (2022) (1)
Axonal Integrity and Fractional Anisotropy in the Normal-Appearing White Matter of Patients with Multiple Sclerosis : Relationship to Cerebro-Functional Reorganization and Clinical Disability (1999) (1)
Improvement in Clinical Outcomes Following Switch From Subcutaneous Interferon Beta-1a to Alemtuzumab: CARE-MS II Extension Study (P7.278) (2015) (1)
Patients with Active RRMS and an Inadequate Response to Prior Therapy Who Received Alemtuzumab Demonstrate Durable Suppression of New MRI Lesion Formation: 5-Year Follow-Up of the CARE-MS II Study (P3.112) (2016) (1)
Cortical Surface Analysis of Multi-contrast MR Data to Improve Detection of Cortical Pathology in Multiple Sclerosis (2013) (1)
Alemtuzumab Reduced MRI Lesions and the Rate of Brain Volume Loss in CARE-MS II Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) (P5.031) (2018) (1)
Four‐neighborhood clique kernel: A general framework for Bayesian and variational techniques of noise reduction in magnetic resonance images of the brain (2014) (1)
Five-year follow-up of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM, and ENDORSE (2014) (1)
Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (2013) (1)
Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005) (2018) (1)
The Relevance of Normal-Appearing White Matter Pathology in Multiple Sclerosis (2004) (1)
Differential Diagnosis of Human Intracranial Tumors in Vivo Using 1H Mr Spectroscopic Imaging and Feature Space for Spectral Pattern Recognition (1994) (1)
Automated Detection of Focal Cortical Dysplasia based on Textural, Statistical and Morphological Analysis of MRI (2003) (1)
ESTIMATING AND ACCOUNTING FOR THE EFFECT OF MRI SCANNER HARDWARE CHANGES ON LONGITUDINAL WHOLE-BRAIN ATROPHY MEASUREMENTS (2016) (1)
Patients Who Switched from SC IFNB-1a to Alemtuzumab in the CARE-MS II Extension Study Show Durable Improvements in Clinical Outcomes (P3.024) (2016) (1)
Results from the 48-Week Blinded Extension of RADIANCE: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis (P3.023) (2016) (1)
Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study (2017) (1)
No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment: Long-Term Responders from the CARE-MS II Study (P3.059) (2016) (1)
Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. (2021) (1)
Effects of oral ELND005 (Scyllo-inositol) on brain scyllo-inositol and myo-inositol levels: Spectroscopy results from a phase 2 study in MILD-TO-MODERATE Alzheimer's disease (2012) (1)
Robust automatic segmentation of hippocampus from multisite MRI data (2009) (1)
Predicting disability progression and cognitive worsening in multiple sclerosis using grey matter network measures (2021) (1)
Sleep-Disordered Breathing (SDB) and Fatigue in Multiple Sclerosis (MS). (2009) (1)
Sustained Low Rate of Brain Volume Loss under Long-term Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis Patients: Results from the ENDORSE Study (P7.243) (2015) (1)
Primary Analysis of a Randomized Phase II Study to Evaluate the Efficacy and Safety of Evobrutinib, a BTK Inhibitor, in Patients with Relapsing MS (2019) (1)
Three-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated magnetic resonance imaging (MRI) outcomes from DEFINE, CONFIRM, and ENDORSE (2013) (1)
Multiple Sclerosis Therapeutics: Axonal pathology in patients with multiple sclerosis (2011) (1)
Proton Magnetic Resonance Spectroscopic Imaging and Magnetic Resonance Imaging Volumetry in the Lateralization of Temporal Lobe Epilepsy : A Series of 100 Patiekts (2004) (1)
Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning (2022) (1)
MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial (2023) (1)
P.107 Personalized prediction of future lesion activity and treatment effect in multiple sclerosis from baseline MRI (2022) (1)
Adapted MRF Segmentation of Multiple Sclerosis Lesions Using Local Contextual Information (2011) (1)
Contents Vol. 53, 2005 (2005) (1)
Effect of Interferon beta-1b and Glatiramer Acetate on New MTR Brain Lesions in MS (P07.104) (2013) (1)
Results of the 48-Week Blinded Extension of RADIANCE: a Randomized, Placebo-controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis (2016) (0)
Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis (2022) (0)
Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study (2021) (0)
Durable Reduction in MRI Disease Activity and Slowing of Brain Volume Loss in Alemtuzumab-Treated Patients With Active RRMS: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) (P6.375) (2018) (0)
060 Association of brain volume loss and neda outcomes in patients with relapsing multiple sclerosis in the opera i and opera ii studies (ENCORE) (2018) (0)
The Axonal Hypothesis and Magnetic Resonance Spectroscopy of MS (1998) (0)
Alemtuzumab Decreased MRI Disease Activity Over 4 Years in Patients Who Switched From SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up (S12.007) (2017) (0)
Prospective clinical and MRI characterization of children with serum anti-MOG antibodies meeting the multiple sclerosis diagnostic criteria (2018) (0)
Peginterferon Beta-1a Reduces Conversion of MRI Lesions to Black Holes in Patients with Relapsing-Remitting Multiple Sclerosis (P3.091) (2016) (0)
MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results (P6-3.012) (2023) (0)
Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis (P5-3.010) (2023) (0)
Peginterferon Beta-1a Demonstrated Sustained Efficacy in Newly Diagnosed Relapsing Multiple Sclerosis (RMS) Patients Treated up to 4 Years: Subgroup Analysis of ATTAIN (P6.386) (2018) (0)
Estimating treatment effect for individuals with progressive multiple sclerosis using deep learning (2021) (0)
MD1003 in Progressive Multiple Sclerosis: 24-Month Brain Volume Changes of the MS-SPI Trial (P6.365) (2018) (0)
Radiomics-based Unsupervised Clustering of Acute Multiple Sclerosis Lesions (P10-3.015) (2023) (0)
Relapsing-Remitting Multiple Sclerosis Effectively Treated with Peginterferon Beta-1 (2014) (0)
O4-06-02 EFFECTS OF HUMAN INTRAVENOUS IMMUNOGLOBULINS ON AMYLOID PATHOLOGY AND INFLAMMATION IN A MOUSE MODEL OF ALZHEIMER’S DISEASE (2011) (0)
3-Year Follow-up of Oral BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated MRI Outcomes from the DEFINE, CONFIRM, and ENDORSE studies (2014) (0)
Magnetic Resonance Spectroscopy in Niemann-Pick Type C: Corrdation With Di is Clinical Response to Ch styramine and Lovas tin (1994) (0)
Mutations in Females Introduction Pyruvate dehydrogenase (PDH) deficiency is a major (1995) (0)
Letters to the editor (1978) (0)
Fully-automated MRI quantification of lateral-ventricle volume and volume-change in patients with Alzheimer ’ s disease (2009) (0)
Thanks to Reviewers (2002) (0)
Corrigendum to “Intracortical inhibition abnormality during the remission phase of multiple sclerosis is related to upper limb dexterity and lesions” [Clin. Neurophysiol. 127 (2016) 1503–1511] (2017) (0)
GREATER PERIPHERAL THAN CENTRAL ADAPTATION TO AEROBIC TRAINING IN MITOCHONDRIAL MYOPATHIES 186 (1997) (0)
Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies (2022) (0)
Deep Learning Reconstruction of Lesion-Free Representations of the Brain in Multiple Sclerosis Patients (P11-3.006) (2023) (0)
In Relapsing Multiple Sclerosis, Peginterferon Beta-1a Reduces MRI Lesions Following Relapses (P7.256) (2015) (0)
Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up (2020) (0)
Progression Independent of Relapse Activity (PIRA) in Patients with Relapsing Multiple Sclerosis (2019) (0)
Imaging and cerebrospinal fluid biomarker results of a phase II dose-ranging study of ELND005 (Scyllo-inositol) in mild-to-moderate Alzheimer's disease (2011) (0)
Prediction of Progression in Multiple Sclerosis Patients (2018) (0)
The effect of head positioning and repositioning on SIENA-generated measures of brain volume change: Results from simulated Z-shifts (2009) (0)
Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions (2022) (0)
Measuring Brain Volume in Patients with Multiple Sclerosis: A Comparison of Three Common Approaches (2009) (0)
Proteogenomic immune signatures delineate the landscape of pediatric acquired demyelinating syndromes (2022) (0)
PR_144: The Association of Fatigue With Brain Metabolites in Postpoliomyelitis Syndrome (2006) (0)
Subject Index Vol. 53, 2005 (2005) (0)
The Spatial Statistics of Structural Magnetic Resonance Images: Application to Quality Assessment of Brain MRI Images (2016) (0)
Chapter 54 MRS for imaging neuronal dysfunction in epilepsy (2002) (0)
Daclizumab HYP reduces total disability burden of patients with multiple sclerosis: results from an exploratory area under the curve analysis (2015) (0)
An integrated analysis of the clinical and neuroradiological effect of BG-12 (dimethyl fumarate) in subgroups of patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINE and CONFIRM studies (2013) (0)
Diroximel Fumarate (DRF) in Patients With Relapsing-Remitting Multiple Sclerosis: Interim Efficacy and Safety Results From the Phase 3 EVOLVE-MS-1 Study (P3.2-060) (2019) (0)
Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study) (2019) (0)
MRI evidence that gadolinium-enhancing lesions seen twelve weeks after commencing rituximab treatment are associated with lower blood-brain-barrier disruption than those seen prior to treatment in patients with relapsing-remitting multiple sclerosis (2008) (0)
Peginterferon Beta-1a Significantly Increases the Proportion of Patients with Freedom from Measured Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the ADVANCE Study (S4.007) (2014) (0)
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. (2023) (0)
Data from: Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice (2019) (0)
Functional Magnetic Resonance Imaging and Multiple Sclerosis: Cortical Reorganisation and Recovery (2001) (0)
The effect of head positioning and repositioning on SIENA-generated measures of brain volume change: Results from actual Z-shifts (2009) (0)
MOG-IgG1 antibodies in children. (2018) (0)
Myelin Water Fraction of Slowly Evolving Lesions is Associated With Disability in Multiple Sclerosis (P10-3.017) (2023) (0)
Heatmap Regression for Lesion Detection using Pointwise Annotations (2022) (0)
Clinically Plausible Pathology-Anatomy Disentanglement in Patient Brain MRI with Structured Variational Priors (2022) (0)
Precision of longitudinal measures of cortical grey matter thickness change and ventricular volume change: comparison to the difference of cross-sectional measures, using multicenter scan-reposition-rescan MRI data (2010) (0)
Magnetic resonance spectroscopy in epilepsy (2002) (0)
Subgroup and Sensitivity Analyses of the Primary Endpoint from the Peginterferon Beta-1a ADVANCE Study: A Pivotal Phase 3 Study in Patients with Relapsing-Remitting Multiple Sclerosis (P3.169) (2014) (0)
Robust automatic segmentation and characterization of lateral ventricle size in the ADNI cohort (2010) (0)
IC-P-013 Greater frontal than cingulate magnetic resonance spectroscopy abnormalities in early Alzheimer disease (2006) (0)
Early Clinical and MRI Predictors of Time to Second Attack and Disability in Children with Acute Demyelinating Syndromes: Findings from a Prospective National Cohort Study (S54.007) (2014) (0)
Abnormal responses of CD8+CD161high mucosal associated invariant T (MAIT) cells and CCR2+CCR5+ CD4 T cells contribute to disrupted balance of effector and regulatory T cells in pediatric-onset MS (2014) (0)
Differential Regional Brain Atrophy Following Prophylactic Cranial Irradiation in Small Cell Lung Cancer Patients (2008) (0)
PO127 Composite confirmed disability progression in oratorio (2017) (0)
Patients Who Discontinued SC IFNB-1a and Switched to Alemtuzumab in the CARE-MS II Extension Study Show Durable Reduction in New Lesion Activity (P3.025) (2016) (0)
Combining SIENA and SIENAx for improved quantification of grey and white matter atrophy (2011) (0)
Sleep-disordered Breathing Is Associated With Pain In Multiple Sclerosis (2010) (0)
MRI, Efficacy, and Safety of Tolebrutinib in Patients with Highly Active Disease (HAD): 2-Year Data from the Phase 2b Long-term Safety (LTS) Study (P6-3.017) (2023) (0)
Imaging biomarkers in multiple sclerosis (2010) (0)
Using Deep Learning Algorithms to Automatically Identify the Brain MRI Contrast: Implications for Managing Large Databases (2018) (0)
Coenzyme Q (1993) (0)
Acknowledgment: List of Reviewers (2006) (0)
Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters (2018) (0)
Rethinking Generalization: The Impact of Annotation Style on Medical Image Segmentation (2022) (0)
Active RRMS Patients Treated with Alemtuzumab Experience Durable Reductions in MRI Disease Activity and Slowing of Brain Volume Loss: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (P6.367) (2018) (0)
4-Year Follow-up of Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Magnetic Resonance Imaging (MRI) Outcomes From DEFINE, CONFIRM, and the ENDORSE Extension Study (P3.160) (2014) (0)
Retinal Nerve Fiber Layer (RNFL) and Ganglion Cell Inner Plexiform Layer (GCIPL) in Persistently Myelin Oligodendrocyte Glycoprotein Antibody Positive Youth (P3.330) (2018) (0)
Predicting personalised risk of disability worsening in multiple sclerosis with machine learning (2022) (0)
Effects of Fingolimod on MRI Outcomes in Patients with Pediatric Onset Multiple Sclerosis: Results from Phase 3 PARADIGMS Study (S51.005) (2018) (0)
Clinical Research Relation of Interictal Spike Frequency to H-MRSI-Measured NAA/Cr (1999) (0)
Development Of Silent Brain Lesions In Pediatric Patients With Antibodies To Myelin Oligodendrocyte Glycoprotein (2020) (0)
Treatment with Alemtuzumab Leads to Durable Benefits in Patients with Multiple Sclerosis (2014) (0)
Serum 25‐hydroxyvitamin D as a determinant of multiple sclerosis outcome following a pediatric demyelinating event (2009) (0)
Reply: To PMID 24006277. (2014) (0)
069 Peginterferon beta-1a improves clinical and radiological disease outcomes in patients who are newly diagnosed with relapsing-remitting multiple sclerosis (RRMS): subgroup analysis of advance (2018) (0)
Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS (P6-3.013) (2023) (0)
200 AFFINITY: opicinumab in a targeted population of MS patients (2019) (0)
A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS (2016) (0)
Patterns of white and gray structural abnormality associated with paediatric demyelinating disorders (2022) (0)
2010 McDonald Criteria for Diagnosing Pediatric Multiple Sclerosis (P01.155) (2012) (0)
Astrocytic Brain Tumors and Isolated Demyelinating Lesions of the Type Seen in Multiple Sclerosis Using H Magnetic Resonance Spectroscopic Imaging 1 (2004) (0)
P2-324 Greater frontal than cingulate magnetic resonance spectroscopy abnormalities in early Alzheimer’s disease (2006) (0)
Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. (2023) (0)
P1-225: Effects of actual and simulated Z-shifts on freesurfer-segmented whole-brain-tissue, hippocampal, and lateral-ventricle volumes (2008) (0)
Localization and Registration Issues Important for Serial MRS Studies of Focal Brain Lesions (2007) (0)
Reply (2014) (0)
The effect of head positioning and repositioning on SIENA-generated measures of brain volume change: Results from actual Z-shifts (2009) (0)
Phenotypic and Functional Analysis of Immune Cell Subsets in Pediatric-onset Multiple Sclerosis (MS): Towards Definition of Earliest Disease Mechanisms (P2.236) (2014) (0)
Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120) (2013) (0)
The effect of head positioning and repositioning on SIENA-generated measures of brain volume change: Results from simulated Z-shifts (2009) (0)
INDICES CORRELATE WITH PHYSICAL ACTIVITY (0)
ADVANCE Trial: PEG-IFN- -1a Every 2 Weeks Significantly Improved Outcomes over 2 Years in RRMS (2014) (0)
136 NOVA primary results randomised controlled study of natalizumab Q6W versus continued Q4W treatment for MS (2022) (0)
Diffusion Tensor Imaging: Abnormal White Matter at the Time of a First Attack Distinguishes Children with Multiple Sclerosis from Children with Monophasic Demyelination and from Healthy Children (S50.007) (2012) (0)
2-13-02 Correlation between brain axonal damage and central nervous system impairment in brain white matter disorders (1997) (0)
Influence of the training library composition on a patch-based label fusion method: Application to hippocampus segmentation on the ADNI dataset (2011) (0)
A RARE PRESENTATION OF A RARE DISEASE: ADULT ONSET KRABBE ’ S DISEASE PRESENTING WITH PROGRESSIVE HYPERTROPHIC POLYRADICULONEUROPATHY TAKOTSUBO CARDIOMYOPATHY AND MYASTHENIC CRISES: A CASE SERIES IMPAIRED COLOR DISCRIMINATION IS ASSOCIATED WITH HALLUCINATIONS IN DEMENTIA WITH LEWY BODIES (2020) (0)
Lateral ventricle segmentation based on fusion of expert priors in AD . (2009) (0)
Effectiveness of Intensity Normalization on Human Brain MRIs with Multiple Sclerosis (2009) (0)
Evidence Of Impaired Age-Expected Growth And Atrophy Of The Cerebellum In Pediatric Patients With Monophasic Acquired Demyelinating Syndrome And Multiple Sclerosis (S60.001) (2014) (0)
Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN. (2021) (0)
Adaptive local reorganisation of primary motor cortex after brain injury (2000) (0)
Simulation-based power analysis could improve the design of clinical trials in Alzheimer's disease (2022) (0)
Lack of Rebound Disease Activity in Participants with Relapsing Multiple Sclerosis Following Placebo Run-out in the Tolebrutinib Phase 2b Trial (P6-3.006) (2023) (0)
MRI Features Distinguish Monophasic ADEM from MS: Findings from a Canadian Cohort of Children with Incident CNS Demyelination (S50.002) (2012) (0)
DECIDE: Significantly Improved Brain MRI Results with DAC HYP versus Interferon in RRMS (2014) (0)
IC-P2-083: Effects of actual and simulated Z-shifts on freesurfer-segmented whole-brain tissue, hippocampal, and lateral-ventricle volumes (2008) (0)
4-year follow-up of delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis (RRMS): integrated MRI outcomes from DEFINE, CONFIRM, and the ENDORSE extension study (2014) (0)
Biomarkers in Pediatric Multiple Sclerosis: Predicting Recurrent Disease at the Initial Demyelinating Episode (2010) (0)
Chapter 6. Use of Imaging in Multiple Sclerosis (2008) (0)
Anti-MOG IgG1 Antibodies in Children (2019) (0)
Peginterferon beta-1a reduces the number of black holes evolved from acute MRI lesions in newly diagnosed patients with relapsing-remitting multiple sclerosis: A post hoc analysis ADVANCE (2019) (0)
Efficacy and Safety of Ozanimod: Results From the 2-Year Blinded Extension of RADIANCE, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Relapsing Multiple Sclerosis (S24.008) (2017) (0)
Alemtuzumab Improves Clinical and Radiological Outcomes in Patients with Relapsing-remitting Multiple Sclerosis Over 8 Years: Care-MS I Follow-up (topaz Study) (2018) (0)
Progressive retinal changes in pediatric multiple sclerosis. (2022) (0)
Precision of Longitudinal Measures of Cortical Grey Matter Thickness Change and Ventricular Volume Change: Comparison to the Difference of Cross-Sectional Measures, Using Multicenter Scan-Reposition-Rescan MRI Data (2010) (0)
Late Breaking News (2015) (0)
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial (2022) (0)
Robust fusion of Jacobian maps for Deformation-Based Morphometry (2011) (0)
Nonlinear Normalization of Magnetization Transfer Ratio Images for Multi-Centre Clinical Trials (2012) (0)
R E V I E W A R T I C L E 1 H-MRS quantiﬁcation of tNA and tCr in patients with multiple sclerosis: a meta-analytic review (2005) (0)
Evobrutinib reduces volume of slowly expanding lesions (2022) (0)
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis Over 48 Weeks: A Randomized, Placebo-Controlled, Phase 2 Study (2020) (0)
31P-NMR studies in patients with exertional muscle pain syndrome (EMPS) responding to verapamil. (1987) (0)
Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension (S16.008) (2023) (0)
The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics (P6.344) (2017) (0)
Poster 271 Post‐Poliomyelitis Syndrome Is Not Associated With Brain Atrophy (2012) (0)
ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS (2016) (0)
Single-timepoint low-dimensional characterization and classification of acute versus chronic multiple sclerosis lesions using machine learning (2022) (0)
Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis (1337) (2020) (0)
T-cell antigens in pediatric-onset multiple sclerosis: A unique window into early disease mechanisms (2017) (0)
Adverse early life events are not associated with pediatric multiple sclerosis (MS) (P3.217) (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Douglas L Arnold?

Douglas L Arnold is affiliated with the following schools:

Douglas L Arnold's Academic­Influence.com Rankings

Douglas L Arnold's Degrees

Why Is Douglas L Arnold Influential?

Douglas L Arnold's Published Works

Published Works

What Schools Are Affiliated With Douglas L Arnold?

Douglas L Arnold's AcademicInfluence.com Rankings